Pratima Chowdary
Royal Free London NHS Foundation Trust · 311 works · 10,200 citations · h-index 43
Top works
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
- Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
- Guideline for the diagnosis and management of the rare coagulation disorders
- Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
- Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
- Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
- Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19
- Efficacy and safety of OBI ‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
- Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A
- Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?
- Evaluation of coagulation abnormalities in acute liver failure
- The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
- Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer
- PB0056 Predicting VTE and Mortality in COVID-19 by Receiver-Operating Characteristic (ROC) Analysis of Haemostatic and Inflammatory Biomarkers
- Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
- OC 69.5 Outcomes in Adult and Adolescent Patients with Severe Hemophilia a in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis from an Observational Study with Factor VIII Prophylaxis
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
- Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A